The new building measuring 30,000 sq ft., located at Grifols’ industrial complex in Clayton, NC, will allow the company to increase its human plasma fractionation capacity in North America.
Sergi Roura, President of Grifols Therapeutics Inc., presented the IDF Board of Trustees with an overview of how they manufacture plasma-derived therapies, like those used to treat primary immunodeficiency diseases. The group then embarked on a comprehensive tour of the plant, led by Joe Barbour, Senior Manager, Manufacturing. The visit was graciously organized by Joe Zuraw and Gail Moore of Grifols Department of Patient Relations.
The IDF Board of Trustees was in town for a meeting and the IDF Volunteer Leadership Conference, which was sponsored by Grifols.
Overall the visit to the Grifols' facility gave the Board a first-hand look at the complex production process of plasma-derived therapies. The Board members were impressed with the new plant and the high standards of both quality and technology.